x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Apr 18, 2016 3:03 EST

TecMed, Inc. – Focused on the creation, development, and commercialization of eminently accurate, automated, real-time, cost-effective blood glucose measurement and monitoring technologies

iCrowdNewswire - Apr 18, 2016

TecMed, Inc. Logo

 

Cheyenne, WY 82001, US
Medical Devices & Equipment
www.tecmed.com

TecMed, Inc. is a privately held intellectual property (IP) company focused on the creation, development, and commercialization of eminently accurate, automated, real-time, cost-effective blood glucose measurement and monitoring technologies.

 

TecMed, Inc. Image 1

TecMed, Inc. Image 2

TecMed, Inc. Image 3

TecMed, Inc. Image 4

TecMed, Inc. Image 5

TecMed, Inc. Image 6

TecMed, Inc. Image 7

TecMed, Inc. Image 8

TecMed, Inc. Image 9

TecMed, Inc. Image 10

TecMed, Inc. Image 11

 

Our primary focus now is the creation of business relationships with commercialization partners for automated clinical IP which allows for increased accuracy, reliability and cost effectiveness in hospitalized patient blood glucose measurement. The early designs incorporating our core technology and patented scientific principles have consistently demonstrated precision in measurement far superior to current measurement devices and technologies.

Our core technology began as The Sentinel, a non-invasive consumer glucose measurement device. This technology led into the development and refinement of IP designed specifically for automated blood glucose measurement before, during and after surgical procedures and in critical care units. Research consistently shows that properly managed blood sugar reduces healthcare costs and improves patient outcomes. Today, there are no patient monitoring solutions that provide this data with sufficient accuracy, immediacy, or frequency to achieve necessary blood sugar goals. Moreover, current methods are labor intensive, expensive, and lack the accuracy that our IP provides. In fact, the accuracy of TecMed’s patented and patent pending clinical measurement IP has been demonstrated in more than 30 human trials. In this unserved global market, currently valued at nearly $3B, we are the only organization that has met the current US government regulatory specifications for glucose measurement accuracy in critical care environments.

Over 380 shareholders have invested more than $67M in the creation and refinement of core technologies for utilization in this $15B industry. As we transition from research and development to marketing, we are actively seeking commercialization partners. Our IP for non-invasive consumer, automated clinical patient, and other medical measurement and monitoring designs are ready to be transferred to others for utilization in adaptive medical device design development, manufacturing and monetization.

 

Summary

Prior Year Revenue Current Year Revenue Next Year Revenue
Company Age Employees Sub-Industry
20 years, 8 months 15 Patient Monitoring
Company Type Stock Exchange Stock Symbol
Privately-Held

 

Products / Services

Automated Surgical and Critical Care Glucose Measurement IP – The “Clinical Sentinel IP”

TecMed’s automated perioperative and critical care glucose management IP is a highly advanced measurement and monitoring platform that is now ready to be commercialized to others for final design development, manufacture, and distribution. This refined IP provides our commercialization partners a flexible platform that can be built into existing patient monitoring systems or as a stand-alone design. The patented and patent pending core intellectual property has repeatedly demonstrated accuracy exceeding all current and proposed regulatory measurement specifications for critical and intensive care patient monitoring.

Non-Invasive Consumer Diabetic Blood Glucose Monitor – The “Consumer Sentinel IP”

Product development has also continued for additional device designs and applications that are in various stages of development including diabetic self-monitoring called the Consumer Sentinel IP. This IP represents a fundamental departure from the expensive, inconvenient, and painful fingerstick method. In vivo human studies have validated TecMed’s method and instrumentation for non-invasive glucose measurement. This IP is designed to provide the user an accurate and direct readout of blood glucose levels within seconds as often as necessary or desired without additional cost for disposables.

 

News / Links

Management

Chief Executive Officer
Alan J. Leszinske

Mr. Leszinske’s business experience includes corporate management, small business start-ups, investment banking, and capital formation, as well as a deep background in technology conceptualization, incubation and maturation. He currently shares authorship of four patents related to the core technology of the Company, and as sole author of two additional patent applications. Mr. Leszinske brings not only management, investment and administrative skills, but also scientific expertise and technical direction to the Company. Mr. Leszinske’s background includes engagements from Researcher to Principal Scientist/Investigator involved in university, NASA, DARPA, and private industry sponsored projects. Mr. Leszinske is the Company’s founder, majority shareholder, primary financier, and has served as President and CEO of TecMed, Inc. for eighteen years. He has served on the Company’s Board of Directors since its inception and is currently serving as Chairman.

Director Marketing
Steven Schroeder

Mr. Schroeder brings to TecMed nearly forty years of experience in the medical device industry. The vast majority of his background and expertise is specifically in the marketing, sales, marketing management, and distribution of cardiovascular surgical products and devices. Previously, Mr. Schroeder was a partner at BlauKaptainSchroeder, and as Vice President of Marketing at Lukens Medical Corporation, he was part of the executive management team that successfully took that company public

Chief Operating Officer
Thomas L. Tucker

Mr. Tucker is a biochemist with a Masters of Science in Biochemistry. Mr. Tucker brings nearly25 years of experience in the medical device and diagnostics industry as well as other biotechnology fields, including serving as Technology Transfer Liaison in the development of enzyme and antibody based diagnostic test kits and testing devices. Prior to TecMed, Mr. Tucker served in applied research and management capacities for an FDA-registered biotechnology startup company in Santa Fe, New Mexico. Mr. Tucker has served as a director and officer in a number of early stage technology firms over the past decade, including TecMed, Inc., where he has served in a number of scientific, technical, and leadership positions for the past eight years. Mr. Tucker has been elected to serve on the Board of Directors for the past seven years.

Consulting Physician/Medical Officer
Stuart Pett, M.D.

Dr. Stuart Pett has served a member of the Company’s Medical Advisory Board since 2002. Dr. Pett is a Cardiothoracic Surgeon certified by the National Board of Medical Examiners, the American Board of Surgery and the American Board of Thoracic Surgery. He is Chief of Cardiothoracic Surgery and an Attending Surgeon for the Veterans Administration Medical Center, Albuquerque, New Mexico. He is also an Attending Surgeon for the Lovelace Medical Center, University of New Mexico Hospital, and the St. Joseph Medical Center in Albuquerque. Dr. Pett serves as part of the Medical Consultant Staff for the Veterans Administration Medical Center in Big Spring Texas. Dr. Pett is a Professor Emeritus for the University of New Mexico School of Medicine. He is the holder of multiple patents and a published medical author.

Consulting Physician/Medical Officer
Vincent Figueredo, M.D.

Dr. Vincent Figueredo has served actively on the Company’s Medical Advisory Board since 2003. Dr. Figueredo is Director of the Cardiovascular Diseases Fellowship Programs, Associate Chair of Cardiology at Einstein Medical Center and Professor of Medicine at Jefferson Medical College in Philadelphia, Pennsylvania. Dr. Figueredo is a member of the medical staff for the Frankford-Torresdale Hospital and the Nazareth Hospital in Philadelphia. Dr Figueredo is a member of the Greater Philadelphia Cardiology Associates, the American Society of Echocardiography, the American College of Cardiography, the American Society of Nuclear Cardiology, the American Society of Hypertension, and the Clinical Cardiology Council for the American Heart Association. Dr. Figueredo is also an Affiliate Member of the Ernest Gallo Clinic and Research Center. In addition to being a patented inventor he is a widely published medical researcher and author.

Consulting Advisor
Robert J. Dragan, BS, CCP

Robert Dragan has served as a medical consultant and member of the Company’s Medical Advisory Board since 2005. Mr. Dragan is a Certified Clinical Perfusionist and member of the American Board of Cardiovascular Perfusion. He recently retired as Chief of Pediatric Perfusion and the Technical Coordinator of the ECMO Program at the University of New Mexico Medical Center. Mr. Dragan is a former Clinical Instructor for Ohio State University and conducted presentations in his field for AMSECT International meetings and Conferences as well as the University of New Mexico. Mr. Dragan is a published author and travels worldwide, volunteering his services and expertise as a perfusion specialist in exceptionally challenging neonatal and pediatric cardiothoracic surgical procedures.

Consulting Physician/Medical Officer
Jeremy Gleeson, M.D.

Dr. Gleeson is Chairman of Endocrinology and Associate Medical Director for Medical Specialities at Lovelace Healthcare; a major regional medical and research center. He is Fellow of the College of Endocrinology and College of Physicians, and Board Certified in Endocrinology and Metabolism. Dr. Gleeson is Chairman of the New Mexico Diabetes Advisory Council and President of the New Mexico affiliate of the American Diabetes Association. Dr. Gleeson is well published in the area of Diabetes, and is the immediate past President of the Albuquerque Medical Association
Dr. Gleeson has been selected to the Albuquerque Top Docs for 2011 and 2012. In 2012, Dr. Gleeson was selected for the U.S. News and World Reports Top Doctors in America.

Director Media/Communication
Emily Cross, Ph.D.

Dr. Cross is an independent business owner and adjunct professor with real world experience in creating, developing, marketing and managing business startups. In addition, her experience as an educational success coach and independent leadership consultant provides a unique hybrid perspective between academia and entrepreneurial management. Her skills in marketing and communication provide timely strength for the creation, development, and implementation of the Company’s focused marketing campaign. Dr. Cross is also published author and public speaker.

Director
Laurel Hull, Major USMC (Ret.)

Ms. Hull’s experience in making things work within time and budget constraints while serving in the United States Marine Corps, as well as her service as an executive officer and director in the non-profit arena provides real value to the Company. Beginning in 1975, Ms. Hull served in the United States Marine Corps honorably as an Adjutant and retired in 1995 as a Major with a broad array of management, negotiation, administrative and organization skills. During her career, she traveled extensively around the world, had the opportunity to participate in labor-management negotiations and mediation, and provided administrative advice and expertise in a variety of areas. Since retirement, Ms. Hull has worked extensively in veteran organizations and is currently the President of the Marine Corps League Foundation, a 501c(3) organization dedicated to funding scholarships, youth activities, humanitarian aid and disaster relief.

 

 

Contact Information:

Chief Executive Officer
Alan J. Leszinske

View Related News >
support